CTA
BLUE

Carillon Tower Advisers’s bluebird bio BLUE Stock Holding History

Carillon Tower Advisers’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-17,293
Closed -$20.6M – 471
2019
Q3 		$20.6M Hold
17,293
– – 0.14% 242
2019
Q2 		$28.5M Hold
17,293
– – 0.2% 188
2019
Q1 		$35.2M Hold
17,293
– – 0.25% 151
2018
Q4 		$22.2M Buy
17,293
+2,958
+21% +$4.54M 0.19% 203
2018
Q3 		$27.1M Buy
14,335
+2,539
+22% +$5.25M 0.19% 185
2018
Q2 		$24M Hold
11,796
– – 0.19% 190
2018
Q1 		$24.7M Hold
11,796
– – 0.19% 182
2017
Q4 		$27.2K Buy
+11,796
New +$23.9M 0.29% 133

Other funds holding BLUE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carillon Tower Advisers's BLUE Position: Q4 2019 in Review

Carillon Tower Advisers sold out of bluebird bio (BLUE) in Q4 2019, closing a stake of 17,293 shares — an estimated $20.6M sold.

Carillon Tower Advisers first reported a position in BLUE in Q4 2017 and held it in 8 quarters. The position peaked at $35.2M in Q1 2019. 274 funds tracked by Wall St. Rank hold BLUE as of Q4 2019.

  • Carillon Tower Advisers reported no remaining bluebird bio position as of Q4 2019 after selling out during the quarter.
  • Carillon Tower Advisers sold 17,293 bluebird bio shares in Q4 2019, an estimated $20.6M.
  • Carillon Tower Advisers first reported a position in bluebird bio in Q4 2017 and held it in 8 quarters.
  • Carillon Tower Advisers's bluebird bio position peaked at $35.2M in Q1 2019.
  • 274 funds tracked by Wall St. Rank held bluebird bio as of Q4 2019.

Based on Carillon Tower Advisers's 13F filing for Q4 2019, filed 11 Feb 2020.